The abstract is read at the publisher; the summary is JClub's.
Robotic bronchoscopy is positioned as a diagnosis-to-treatment platform for early lung cancer, with “clinically actionable yield” proposed to link access, confirmation, pathology, molecular adequacy, staging, and management decisions.
- Why it matters: Diagnostic yield and safety alone miss whether bronchoscopy supplies enough information for diagnosis, staging, genomic profiling, and immunotherapy-oriented treatment decisions in small, distal, subsolid, and ground-glass nodules.
- What they did: This state-of-the-art review synthesizes evidence on distal airway access, procedural stability, CT-to-body divergence, tool-in-lesion confirmation, cone-beam CT and radial endobronchial ultrasound, plus tissue stewardship, rapid on-site evaluation, cell block preparation, next-generation sequencing, PD-L1 testing, and same-session EBUS-TBNA or EUS-B-FNA.
- The result: It proposes assessing Level 5 endpoints—treatment decision informed or changed—within 30 days after the index procedure or before definitive therapy, and calls for prospective studies using decision- and patient-centered outcomes to validate the reporting construct.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.